Search for: "AstraZeneca Pharmaceuticals, LP" Results 1 - 20 of 97
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Feb 2018, 12:05 pm by Tom Lamb
According to that JPML Transfer Order the Defendants -- AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. -- opposed centralization of approximately 80 Onglyza and Kombiglyze lawsuits into this new MDL: Defendants oppose transfer by arguing that plaintiffs’ allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure – not the various other injuries (congestive heart… [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
12 May 2017, 9:05 am by Tom Lamb
., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. [read post]
6 May 2017, 10:11 am by Lawrence B. Ebert
(“Braintree”) appealsfrom the Southern District of New York’s summary judgmentthat Breckenridge Pharmaceutical, Inc. [read post]
8 Dec 2016, 2:00 am by Linda O'Brien
Linda O'BrienCCHPurchasers of AstraZeneca LP’s heartburn medication Nexium were not entitled to a new trial to their challenge of “reverse payment” agreements between AstraZeneca and Ranbaxy Pharmaceuticals that allegedly blocked the entry of a generic version of the drug, the U.S. [read post]
6 Nov 2016, 10:13 pm by FDABlog HPM
United States Food and Drug Administration, No. 08-01495 (JDB) (here) and AstraZeneca Pharmaceuticals LP v. [read post]
29 Aug 2016, 12:30 pm by Tom Lamb
For use as an example, here is the relevant part of an August 17, 2016 FDA Supplemental Approval letter to AstraZeneca Pharmaceuticals LP for Farxiga: Please refer to your supplemental New Drug Application (sNDA) dated and received July 28 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Farxiga (dapagliflozin) tablets. [read post]
28 Jun 2016, 9:13 am by FDABlog HPM
(“iPR”), the owner of NDA 021366 for CRESTOR (rosuvastatin calcium) Tablets, 5 mg, 10 mg, 20 mg, and 40 mg, and AstraZeneca Pharmaceuticals LP (“AstraZeneca”), iPR’s agent, filed a Complaint in the U.S. [read post]
15 Apr 2016, 8:26 am by Tom Lamb
These medications are available by prescription and over-the-counter (OTC) from various pharmaceutical companies, for example: PRILOSEC (omeprazole magnesium) | prescription drug | AstraZeneca LPPRILOSEC OTC (omeprazole magnesium) | over-the-counter | Procter & Gamble Manufacturing Co.PREVACID (lansoprazole) | prescription drug | Takeda Pharmaceuticals America, Inc.PREVACID 24 HR (lansoprazole) | over-the-counter | Novartis Consumer Health, Inc.NEXIUM (esomeprazole… [read post]
8 Dec 2015, 2:22 pm by Ben Vernia
  AstraZeneca LP and Cephalon Inc. paid the United States $26.7 million and $4.3 million, respectively, in separate settlements for allegedly underpaying rebates owed under the Medicaid Drug Rebate Program. [read post]
27 Feb 2015, 5:02 am by Mary Jane Wilmoth
AstraZeneca to Pay $7.9 Million to Resolve Kickback Allegations AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act. [read post]
13 Feb 2015, 12:00 pm by Greene LLP
AstraZeneca LP et al. was filed under seal on behalf of the federal government in October 2010 by former AstraZeneca employees Paul DiMattia and F. [read post]